Association between Inflammatory Factors, Vitamin D, Long Non‐Coding RNAs, MALAT1, and Adiponectin Antisense in Individuals with Metabolic Syndrome

Rashidmayvan, Mohammad; Khorasanchi, Zahra; Nattagh‐Eshtivani, Elyas; Esfehani, Ali Jafarzadeh; Sahebi, Reza; Sharifan, Payam; Assadian, Parisa; Aghasizadeh, Malihe; Avan, Amir; Ghayour‐Mobarhan, Majid; Ferns, Gordon A.

doi:10.1002/mnfr.202200144

Cited by 2 publications

(1 citation statement)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, there has been tremendous focus on the possible role of MALAT1 in the pathogenesis of metabolic disorders and diabetic models [ 19 , 27 ]. Vitamin D receptor acts as a regulator of MALAT1 gene expression [ 26 , 28 ]. Vitamin D deficiency has been linked to elevated MALAT1 expression in patients with coronary heart disease, and vitamin D intake may be associated with modulation of this inflammatory lncRNA's expression in those patients [ 29 ].…”

Section: Introductionmentioning

confidence: 99%

Double blind control trial of vitamin D fortified milk on the expression of lncRNAs and adiponectin for patients with metabolic syndrome

Rashidmayvan

Sahebi²,

Avan³

et al. 2023

Diabetol Metab Syndr

Self Cite

View full text Add to dashboard Cite

Background Metabolic syndrome (Mets) is a common metabolic disorder in which hypoadiponectinemia is one of the consequences for the body caused by inflammation, and vitamin D may help improve inflammatory symptoms. LncRNAs (long non-coding RNA) play several different regulatory roles in the body. The goal of this study was to see how adding vitamin D to milk affected the levels of adiponectin and inflammatory lncRNAs in the serum of people with Mets. Methods This clinical trial was conducted on staff and students between the ages of 30 and 50 at Mashhad University of Medical Sciences and met the International Diabetes Federation’s criteria for Mets. Eighty-two Mets were assigned randomly to one of two groups for ten weeks: fortified milk (FM) with 1500 IU vitamin D or non-fortified milk (NFM). Total RNA was extracted from both frozen clinical samples using Trizol reagent. APQ AS and MALAT1 lncRNA gene expression were measured by Real-Time PCR. Results Serum adiponectin levels in the FM group increased significantly compared to the NFM group (p = 0.01). Also, the expression of APQ AS and MALAT1 genes decreased after ten weeks, which showed a significant decrease in APQ AS (p = 0.036). Conclusion As in FM, vitamin D may have anti-inflammatory effects and increase adiponectin levels in people with Mets via decreasing APQ AS gene expression.

show abstract

Section: Introductionmentioning

confidence: 99%

Double blind control trial of vitamin D fortified milk on the expression of lncRNAs and adiponectin for patients with metabolic syndrome

Rashidmayvan

Sahebi²,

Avan³

et al. 2023

Diabetol Metab Syndr

Self Cite

View full text Add to dashboard Cite

show abstract

Current Views on Pathophysiology and Potential Therapeutic Targets in Sjögren’s Syndrome: A Review from the Perspective of Viral Infections, Toll-like Receptors, and Long-Noncoding RNAs

Horai,

Shimizu,

Umeda

et al. 2023

JCM

View full text Add to dashboard Cite

Sjögren’s syndrome (SS) is a rheumatic disease characterized by sicca and extraglandular symptoms, such as interstitial lung disease and renal tubular acidosis. SS potentially affects the prognosis of patients, especially in cases of complicated extraglandular symptoms; however, only symptomatic therapies against xerophthalmia and xerostomia are currently included in the practice guidelines as recommended therapies for SS. Considering that SS is presumed to be a multifactorial entity caused by genetic and environmental factors, a multidisciplinary approach is necessary to clarify the whole picture of its pathogenesis and to develop disease-specific therapies for SS. This review discusses past achievements and future prospects for pursuing the pathophysiology and therapeutic targets for SS, especially from the perspectives of viral infections, toll-like receptors (TLRs), long-noncoding RNAs (lncRNAs), and related signals. Based on the emerging roles of viral infections, TLRs, long-noncoding RNAs and related signals, antiviral therapy, hydroxychloroquine, and vitamin D may lower the risk of or mitigate SS. Janus-kinase (JAK) inhibitors are also potential novel therapeutic options for several rheumatic diseases involving the JAK-signal transducer and activator of transcription pathways, which are yet to be ascertained in a randomized controlled study targeting SS.

show abstract

Association between Inflammatory Factors, Vitamin D, Long Non‐Coding RNAs, MALAT1, and Adiponectin Antisense in Individuals with Metabolic Syndrome

Cited by 2 publications

References 62 publications

Double blind control trial of vitamin D fortified milk on the expression of lncRNAs and adiponectin for patients with metabolic syndrome

Double blind control trial of vitamin D fortified milk on the expression of lncRNAs and adiponectin for patients with metabolic syndrome

Current Views on Pathophysiology and Potential Therapeutic Targets in Sjögren’s Syndrome: A Review from the Perspective of Viral Infections, Toll-like Receptors, and Long-Noncoding RNAs

Contact Info

Product

Resources

About